Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index by Garcia, Erwin et al.
 
 
 University of Groningen
Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are
Inversely Associated with Insulin Resistance as Measured by the Lipoprotein Insulin
Resistance Index
Garcia, Erwin; Shalaurova, Irina; Matyus, Steven P.; Oskardmay, David N.; Otvos, James D.;
Dullaart, Robin P. F.; Connelly, Margery A.
Published in:
Journal of Clinical Medicine
DOI:
10.3390/jcm9020321
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Garcia, E., Shalaurova, I., Matyus, S. P., Oskardmay, D. N., Otvos, J. D., Dullaart, R. P. F., & Connelly, M.
A. (2020). Ketone Bodies Are Mildly Elevated in Subjects with Type 2 Diabetes Mellitus and Are Inversely
Associated with Insulin Resistance as Measured by the Lipoprotein Insulin Resistance Index. Journal of
Clinical Medicine, 9(2), [321]. https://doi.org/10.3390/jcm9020321
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the





Ketone Bodies Are Mildly Elevated in Subjects with
Type 2 Diabetes Mellitus and Are Inversely
Associated with Insulin Resistance as Measured by
the Lipoprotein Insulin Resistance Index
Erwin Garcia 1,*,† , Irina Shalaurova 1,†, Steven P. Matyus 1, David N. Oskardmay 1,
James D. Otvos 1, Robin P.F. Dullaart 2,† and Margery A. Connelly 1,†
1 Laboratory Corporation of America Holdings (LabCorp), Morrisville, NC 27560, USA;
shalaui@labcorp.com (I.S.); matyuss@labcorp.com (S.P.M.); oskardd@labcorp.com (D.N.O.);
otvosj@labcorp.com (J.D.O.); connem5@labcorp.com (M.A.C.)
2 Department of Endocrinology, University of Groningen and University Medical Center Groningen, 9700 RB
Groningen, The Netherlands; r.p.f.dullaart@umcg.nl
* Correspondence: garce14@labcorp.com; Tel.: +1-(919)-388-5551
† These authors contributed equally to this work.
Received: 11 December 2019; Accepted: 21 January 2020; Published: 23 January 2020


Abstract: Background: Quantifying mildly elevated ketone bodies is clinically and
pathophysiologically relevant, especially in the context of disease states as well as for monitoring
of various diets and exercise regimens. As an alternative assay for measuring ketone bodies in the
clinical laboratory, a nuclear magnetic resonance (NMR) spectroscopy-based test was developed
for quantification of β-hydroxybutyrate (β-HB), acetoacetate (AcAc) and acetone. Methods: The
ketone body assay was evaluated for precision, linearity and stability and method comparisons
were performed. In addition, plasma ketone bodies were measured in the Insulin Resistance
Atherosclerosis Study (IRAS, n = 1198; 373 type 2 diabetes mellitus (T2DM) subjects). Results: β-HB
and AcAc quantified using NMR and mass spectrometry and acetone quantified using NMR and gas
chromatography/mass spectrometry were highly correlated (R2 = 0.996, 0.994, and 0.994 for β-HB,
AcAc, acetone, respectively). Coefficients of variation (%CVs) for intra- and inter-assay precision
ranged from 1.3% to 9.3%, 3.1% to 7.7%, and 3.8% to 9.1%, for β-HB, AcAc and acetone, respectively.
In the IRAS, ketone bodies were elevated in subjects with T2DM versus non-diabetic individuals
(p = 0.011 to ≤0.001). Age- and sex-adjusted multivariable linear regression analysis revealed that
total ketone bodies and β-HB were associated directly with free fatty acids (FFAs) and T2DM and
inversely with triglycerides and insulin resistance as measured by the Lipoprotein Insulin Resistance
Index. Conclusions: Concentrations of the three main ketone bodies can be determined by NMR with
good clinical performance, are elevated in T2DM and are inversely associated with triglycerides and
insulin resistance.
Keywords: ketone bodies; nuclear magnetic resonance spectroscopy; type 2 diabetes mellitus;
insulin resistance
1. Introduction
Ketone bodies are products of fat catabolism that are used as alternative substrates to glucose
as sources of energy when carbohydrate intake is low and there is a surplus of circulating free fatty
acids (FFAs) [1]. Elevations in ketone bodies occur when there is insufficient insulin to assist in the
utilization of glucose as an energy source (ketoacidosis), during times of prolonged fasting (mild
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ketonemia) or when consuming a carbohydrate restricted diet (ketogenic diet). The predominant
ketone bodies are β-hydroxybutyrate (3-hydroxybutyrate; β-HB), acetoacetate (AcAc) and acetone.
Under normal physiological conditions, total plasma ketone concentrations fluctuate between 100 and
600 µM but can rise to ~1 mM after prolonged exercise or 24 h fasting. Diabetic ketoacidosis is a serious
acute complication that occurs in patients with diabetes and is diagnosed by having ketone body
concentrations >1–1.5 mM. A less common cause of ketoacidosis is due to alcohol abuse, which usually
presents in malnourished patients with a history of a recent alcoholic binge [2,3]. Total ketone body
concentrations can rise as high as 6–20 mM in patients with diabetic or alcoholic ketoacidosis [4,5].
While measurement of ketone body concentrations is critical for diagnosis of ketoacidosis, and
rapid (bedside) tests are widely available, it may also be useful to quantify circulating ketone bodies
when there are only mild elevations. For example, diets that are rich in proteins and fats but low in
carbohydrates (e.g., Atkins diet, also known as a ketogenic diet) have been shown to induce mild
elevations of ketone bodies. Elevations in ketone bodies produced while consuming a ketogenic diet
are much lower than those observed in ketoacidosis and are not associated with a change in blood
pH [6]. Furthermore, ketone bodies may add value to biomarker panels for discerning the metabolic
pathways that are altered in individual patients on exercise, diet or lifestyle management plans as well
as on drug therapy [6,7]. In particular, sodium–glucose cotransporter-2 (SGLT2) inhibitor treatment
for T2DM may elicit ketonemia that is reminiscent of the mild elevations induced by ketogenic diets.
These mild elevations may be related to the ability of SGLT2 inhibitors to reduce plasma glucose
via renal elimination, stimulate lipolysis, elicit weight loss and enhance insulin sensitivity [8–10].
Consequently, physicians or patients may want to monitor ketone bodies to ensure these diets are
managed correctly and are having beneficial effects while not causing very high ketone body levels [11].
Such assays may also be clinically useful while patients are on SGLT2 inhibitor therapy.
Assessment of ketone body concentrations for the diagnosis of ketoacidosis is usually accomplished
using point-of-care urine or blood test strips. These test strips will indicate whether your ketone
body levels are in the normal range or whether they are elevated. However, they are not sensitive
enough to detect mild elevations in ketone bodies that might occur while a patient is on a ketogenic
diet or taking medications that raise ketone body concentrations. In the clinical laboratory, a
colorimetric-spectrophotometric assay can be used as a standalone assay to measure ketone bodies.
A research nuclear magnetic resonance spectroscopy (NMR) platform has also been used for
quantification of ketone bodies and clinical associations were observed [12]. The potential benefit
of using an NMR-based assay in the clinical laboratory is the ability to simultaneously quantify
ketone bodies, glucose, amino acids, lipoproteins and other metabolites, all of which are altered with
diet and drug therapy, from a single NMR spectrum acquired from a serum or plasma specimen.
The NMR signals from the ketone bodies arise from the methyl group protons, and the positions of
these signals within the NMR spectrum are unique and have been well characterized. In addition, the
amplitudes of the signals are proportional to their respective concentrations, which makes quantification
fairly straightforward.
The aims of the current study were to: (1) develop an assay for quantification of the three
main ketone bodies, β-hydroxybutyrate (β-HB), acetoacetate (AcAc) and acetone on a clinical NMR
instrument, (2) to evaluate its analytical performance, and (3) to assess the clinical associations of
ketone bodies with dysglycemia, and insulin resistance in a large, multi-ethnic population.
2. Methods
2.1. Materials and Specimen Collection
β-HB, AcAc and acetone were purchased from Sigma Aldrich (St. Louis, MO, USA). Serum pools
were prepared by identifying and pooling both fasting and non-fasting serum samples with high
and low ranges of the three ketone bodies from donor subjects (LabCorp, Morrisville, NC, USA) or
by spiking.
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2.2. The Insulin Resistance Atherosclerosis Study (IRAS)
The Insulin Resistance Atherosclerosis Study (IRAS) recruited 1625 participants from four clinical
centers located in San Antonio, TX; San Luis Valley, CO; Oakland, CA; and Los Angeles, CA, between
October 1992 and April 1994. Details of the study population, research methods and exclusion criteria
have been published previously [13]. T2DM was defined as fasting plasma glucose (FPG) concentration
≥7.0 mmol/L and/or 2 h glucose concentration ≥11.1 mmol/L by a 75 g oral glucose tolerance test
(OGTT) using World Health Organization criteria [14]. Demographic (e.g., age, sex, ethnicity) and
lifestyle factors (e.g., smoking, alcohol consumption) were collected on standardized questionnaires
by self-report [13,15]. Details of the relevant clinical procedures and laboratory measurements were
described previously [16]. NMR spectra were acquired in the year 2000 from EDTA plasma samples that
were collected after an overnight fast at baseline (1992–1994) (LabCorp, Morrisville, NC, USA) [14,17].
Samples were stored frozen at <−70 ◦C until the time of testing (6–8 years). An internal stability
study revealed that the ketone bodies were stable when frozen at <−70 ◦C for 12 years (<15% bias)
which is longer than the time the IRAS samples were frozen before the NMR spectra were acquired.
Quantification of the three ketone bodies was accomplished by reanalyzing the digitally stored NMR
spectra using the newly developed ketone body assay software algorithm. The sample size of the
current report was 1198 participants after exclusion of subjects that were missing NMR or covariate
data. All participants provided written informed consent and the study was performed according to
the principles outlined in the Declaration of Helsinki. The institutional review boards (IRB) at each
study site approved the study protocol.
2.3. Acquisition of NMR Spectra
The NMR spectra used to quantify the ketone bodies were collected on a Vantera® Clinical
Analyzer (LabCorp, Morrisville, NC, USA), a fully automated, high-throughput, (1H) NMR platform,
in the same manner as the NMR LipoProfile test and branched chain amino acids [16,18–20]. The Vantera
is equipped with a 400 MHz (9.4 T) Agilent spectrometer, a 4 mm indirect detection probe and a flow
cell that was equilibrated at 47 ◦C. The 1D 1H NMR spectra were collected. The water resonance was
attenuated using the WET solvent suppression technique as described previously [19,21]. Each NMR
spectrum was acquired for a total of 48 s (9024 data points, 4496.4 Hz spectral width, 2.95 s relaxation
delay between scans, 12 scans). The free induction decay signal was zero-filled to 32,768 points and
multiplied by a Gaussian function (for resolution enhancement) prior to Fourier Transformation.
2.4. Quantification of Ketone Bodies by Signal Deconvolution Analysis
The methyl signals from the three ketone bodies produce distinct peaks in the 1H NMR spectrum
that can be used for quantification. However, these signals overlap with the NMR signals that arise
from circulating proteins and lipids in the serum sample (Figure 1). Spiking experiments with pure
β-HB, AcAc and acetone in serum confirmed the positions of their signature peaks (Figure 1, insets A
and B). For quantification of the NMR signals for the ketone bodies, a new assay was developed that
mathematically models the peaks for the ketone bodies as well as the underlying background signals
from the lipoproteins, proteins and small molecules in two spectral regions (between 1.14 and 1.17 ppm
for β-HB and 2.18 and 2.24 ppm for AcAc and acetone) and reports levels of β-HB, AcAc, acetone and
total ketone bodies. β-HB can be quantified using signals at 1.13–1.19 ppm as well at 2.33 and 4.13 ppm.
The β-HB signal at 1.13–1.19 ppm was used for quantification because of its simplicity (doublet) and
higher intensity (corresponding to 3 protons) compared to the signals at 2.33 ppm (signal split into 8
peak multiplet components; corresponding to 2 protons) or 4.13 ppm (signal split into 6 peak multiplet
components; corresponding to 1 proton). In addition, in clinical samples it was observed that there
were more peaks (some unknown) overlapping with the β-HB resonance at 2.33 ppm which made
it difficult to quantify on its own. Furthermore, variability in water signal suppression, in addition
to peak overlap, could affect deconvolution when using the β-HB resonance at 4.13 ppm. Moreover,
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using the signal at 1.13–1.19 ppm had the advantage of using a spectral region to measure β-HB that
was separate from the region used to quantify acetoacetate and acetone. The spectral region of interest
in the frequency domain was deconvoluted into its parts by using a non-negative linear least squares
algorithm. The resulting spectral model was generated with the composite lineshapes for the signals
corresponding to ketone bodies and the addition of components comprising each of the background
signals such that the final model coincides closely to the observed NMR signal. As such, the signals
corresponding to the background are, in essence, subtracted during deconvolution and the signal
areas for ketone bodies are subsequently multiplied by their conversion factors to yield concentration
units. Since the peak area correlates linearly with concentration (Figure 2), the conversion factor for
each analyte was determined by calculating the analyte signal area from spectra obtained for dialyzed
serum that were spiked with a known amount of each standard, and relating the area to the expected
concentration of the analyte. The units for the 3 ketone bodies are µM.
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Figure 1. Nuclear Magnetic Resonance (NMR) signal peaks for the three ketone bodies in a spectrum of
serum from a 400 MHz clinical NMR analyzer. The signals from the methyl groups onβ-hydroxybutyrate
(β-HB), acetoacetate (AcAc) and acetone overlap with signals that arise from the protons on lipid
molecules contained within lipoprotein particles (for β-HB) and residues on the backbones and
carbohydrate side-chains of proteins (for AcAc and acetone). Insets: Expanded views of NMR
spectra from serum alone compared to serum spiked with either AcAc (red) and acetone (blue) (single
peaks/singlet; inset (A) or β-HB (green; two peaks/doublet; inset (B) in order to confirm the relative
positions and multiplicity (singlet or doublet) of the signals that were used for quantification. ppm =
parts per million.
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2.5. Determination of LP-IR Scores and GlycA Levels
The Lipoprotein Insulin Resistance Index (LP-IR) is an NMR-based assay that produces scores
that range from 0 to 100 (from least to most insulin resistant) [22]. LP-IR scores are calculated using six
lipoprotein parameters that are quantified by NMR: very-low-density lipoprotein (VLDL), low-density
lipoprotein (LDL) and high-density lipoprotein (HDL) size, along with concentrations of large VLDL,
small LDL and large HDL particles [22]. In addition to LP-IR results being correlated with other indices
of insulin resistance such as Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and
the sensitivity index (Si), LP-IR scores have been shown to predict future T2DM in multiple study
populations [23–26]. GlycA is an NMR-based marker of systemic inflammation whose signal arises
from highly glycosylated acute phase proteins (e.g., α1-acid glycoprotein, haptoglobin, α1-antitrypsin,
and α1-antichymotrypsin) [27]. GlycA levels were quantified as previously described and have been
shown to be related to T2DM and cardiovascular disease [27–29]. LP-IR scores and GlycA levels were
derived from the same NMR spectra from which ketone body concentrations were determined.
2.6. Assay Performance Testing
Dialyz d (through a Slide-A-Lyzer 10 kDa molecular weight cutoff cassette (Thermo Scientific,
Rockford, IL, USA)) serum proteins isolated by ultracentrifugation from five pooled, de-identified
residual serum specimens were used for determining the limits of blank (LOB). Five serum pools
containing low concentrations of β-HB, AcAc and acetone were tested to determine the limits of
detection (LOD) and 12 or more serum pools (AcAc: 18 pools; acetone: 15; β-HB: 12; total ketone
bodies: 16) were used to determine the limit of quantitation (LOQ) according to Clinical and Laboratory
Standards Institute (CLSI) guidelines [30], as previously described [19]. The LOQ was determined
at 20% CV for β-HB and 30% CV for AcAc and acetone, the latter due to the poor precision at low
concentrations and instability. Consistent with CLSI guidelines [31], linearity was evaluated by
identifying serum pools with low and high levels of the ketone bodies and mixing them with the intent
of covering the known biological ranges. In addition, serum pools were spiked individually with
stocks of β-HB, AcAc and acetone in order to achieve the higher concentrations. Mean concentrations
and coefficients of variation (%CVs) were calculated for each pool. Within-run and within-laboratory
imprecision were determined based on CLSI guidelines [32]. Low, intermediate and high pools were
tested for β-HB in order to include a level near the 1–1.5 mM clinical decision point used for diagnosing
ketoacidosis and low and high pools were used for AcAc and acetone. Within-run (intra-assay or
within run) imprecision was determined by analyzing each of the pools on one day and one instrument
(n = 20). The same pools were analyzed for 20 days, two replicates twice per day, (total n = 80) to
evaluate the within-laboratory (inter-assay or between runs) imprecision. In order to avoid instability
issues, especially for AcAc and acetone, aliquots of the various pools were kept frozen until testing.
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2.7. Method Comparison
Method comparison studies, consistent with CLSI guidelines [33], were performed to compare
ketone body quantification by NMR versus liquid chromatography coupled to tandem mass
spectrometry (LC/MS/MS) or gas chromatography/mass spectrometry (GC/MS). The LC/MS/MS
analysis was performed on a Waters Quattro Premier XE employing the High Performance Liquid
Chromatography tandem Mass Spectrometry (HPLC-tMS) method in the Multiple Reaction Monitoring
(MRM) setting. The internal standard solution was prepared in 0.1% formic acid. Each sample (100 µL)
was spiked with 50 µL internal standard solution, vortexed (5 min) and incubated at 4 ◦C for 10 min.
After incubation, 250 µL of 70% HClO4 was added to each sample, vortexed (10 min) and incubated
at 4 ◦C for 10 min. The samples were then centrifuged at 13,400× g at 4 ◦C for 10 min. A 400 µL
clear supernatant was transferred into the HPLC autosampler vial for LC/MS/MS analysis. For the
GC/MS analysis, a Shimadzu 2010 plus GC system was used with a QP-2010 mass detector and an
AOC5000 auto-sampler. The MS parameters were: m/z +43 for quantify and +58 for reference. The ion
source (EI) temperature was 230 ◦C and the GC parameters included a DB-WAX 30 m × 250 µm
× 0.25 µm column with a flow rate of 1.0 mL/min and a column temperature of 160 ◦C. Standard
curves were run at the beginning and end of each run and quality control checks were run every 8
samples. EDTA plasma specimens were obtained from 50 donors and aliquots were immediately
frozen at <−70 ◦C until the time of analysis. Some samples were spiked with the three analytes in
order to reach the highest concentrations. The same frozen plasma samples were analyzed via NMR
(LabCorp, Morrisville, NC) and LC/MS/MS (Creative Proteomics, Shirley, NY, USA) for β-HB and AcAc
(n = 50) or GC/MS for acetone (n = 27) (Creative Proteomics, Shirley, NY, USA). Deming regression
analysis and Bland–Altman plots were used to evaluate the correlations between the results from the
different platforms.
2.8. Comparison of Specimen Collection Tubes and Stability Testing
Blood from 27 donors was drawn into four different tubes: a black and yellow-top Greiner serum
collection tube (part #456293P), also known as a LipoTube (Greiner Bio-One, Monroe, NC, USA),
as well as a red-top BD Vacutainer plain serum tube (no gel barrier), a purple-top K2EDTA plasma
tube and a green-top sodium heparin tube (Becton Dickinson, Franklin Lakes, NJ, USA). In order to
expand the range of measured values, 10 specimens were spiked with stocks of the 3 ketone bodies
(<5% by volume) for a total of 37 specimens. Results from samples collected in plain serum, EDTA
plasma and heparin plasma tubes were compared to results from the Greiner LipoTubes by linear
regression. Specimens from 9 donors (3 donors per analyte; drawn in LipoTubes) were used to assess
specimen/analyte stability. Serum samples were stored at room temperature or refrigerated (4–8 ◦C)
and aliquots were tested hourly and daily. Specimens were also tested after freezing at <−70 ◦C for
15 days and after 3 freeze–thaw cycles. Mean results for all donors were evaluated with acceptable
differences falling within ±10% of the day 0 (draw day) mean. To assess long-term frozen stability,
EDTA plasma samples from an apparently healthy study population were tested and then frozen at
<−70 ◦C for 3 and 6 years.
2.9. Reference Interval Studies
To determine the reference intervals for the analytes reported by the ketone body assay, samples
were analyzed from a cohort of generally healthy adult men and non-pregnant women between the
ages of 18 and 84 who were recruited as volunteer donors. The non-fasting serum samples used
for this analysis were collected in Greiner LipoTubes (described above) and processed as prescribed
by the manufacturer. A description of this study population has been reported [19]; subjects that
were excluded from the original study based on body mass index (BMI) and blood pressure criteria
or whether or not they were taking lipid altering medications were not excluded from this study.
The number of subjects used for this analysis was 552; 337 females and 215 males. The NMR spectra for
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these study samples were acquired on fresh samples and then stored digitally for potential future use.
Quantification of the three ketone bodies was accomplished by reanalyzing the digitally stored NMR
spectra using the newly developed ketone body assay software algorithm. The reference intervals
were estimated using non-parametric analyses with reference limits at the 2.5th and 97.5th percentiles
according to CLSI guidelines [34]. Reference intervals were compared by assessing their median results
using the Wilcoxon–Mann–Whitney and Kruskal–Wallis tests. Reference intervals were confirmed in
177,000 NMR spectra collected over several months in the clinical NMR laboratory from fasting and
non-fasting individuals whose serum samples were received for the NMR LipoProfile test. The protocol
for collection of the samples for this study was approved by an IRB.
2.10. Statistical Analyses
Statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, NC, USA) and Analyze-it
v5.10 (Analyze-it Software, Ltd., Leeds, UK). For the analytical validation studies, linear regression
analyses were performed for comparisons between variables. For the epidemiological studies,
data are expressed as the mean ± SD (or SEM for figures) or as the median (interquartile range).
Skewed variables were natural log (Ln) transformed. Between-group differences in continuous
variables were determined by unpaired t-tests. Between-group differences in dichotomous variables
were determined by χ2-analysis. Univariate analyses were conducted using Spearman correlation
coefficients. Multivariable linear regression analyses were performed to determine the independent
associations of total ketone bodies,β-HB, AcAc and acetone with various clinical parameters. Two-sided
p-values < 0.05 were considered statistically significant.
3. Results
3.1. Ketone Body Assay Development and Performance Characteristics
The signals from the methyl groups of β-HB, AcAc and acetone overlap with signals from proteins,
carbohydrate residues and lipoproteins in the 1D 1H NMR spectrum of serum (Figure 2). Therefore,
a new NMR-based deconvolution assay was developed that mathematically quantifies the signals
from, and concentrations of, each individual ketone body in the context of the lipoprotein and protein
signals in each plasma or serum sample (Figure 2). The limits of blank (LOB) for total ketone bodies,
β-HB, AcAc and acetone as reported by this assay were determined to be 40.1, 27.9, 15.7 and 5.6 µM,
respectively. The analytical sensitivity or limits of detection (LOD) were calculated to be 61.2, 45.0,
24.8 and 11.2 µM. The functional sensitivity or limit of quantitation (LOQ) for total ketone bodies,
β-HB, AcAc and acetone was determined to be 65.0, 45.0, 26.3 and 19.7 µM, respectively. Linearity was
demonstrated between 51.0 and 10,445 µM for β-HB, 52.0 and 4715 µM for AcAc and 6.0 and 8943 µM
for acetone, which span the range of values typically observed in the clinical laboratory (Supplementary
Figure S1A–C). The correlation coefficients (R2) were 1.00 for all three analytes. Based on the linearity
and LOQ data, the reportable ranges for β-HB, AcAc and acetone are 51.0 and 10,445 µM (0.53–108.7
mg/dL), 52.0 and 4,715 µM (0.53–48.1 mg/dL) and 19.7 and 8,943 µM (0.03–51.9 mg/dL), respectively.
Sample pools with low and high levels for AcAc and acetone or low, intermediate and high levels for
β-HB were tested for intra- (within-run) and inter-assay (within-lab) precision. For β-HB, AcAc and
acetone, the CVs for intra-assay and inter-assay precision were 1.3%–9.3%, 3.1%–7.7%, and 3.8%–9.1%,
respectively (Table 1).
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Table 1. Within-laboratory (inter-assay) and within-run (intra-assay) imprecision for the three analytes
reported by the ketone body assay (β-hydroxybutyrate, acetoacetate and acetone).
β-hydroxybutyrate (µM) Acetoacetate (µM) Acetone (µM)
Low Medium High Low High Low High
Within-lab a
Mean 129.5 219.0 1188.9 127.1 182.9 106.5 187.9
SD 12.0 12.9 27.5 9.8 11.2 9.7 12.4
CV (%) 9.3 5.9 2.3 7.7 6.1 9.1 6.6
Within-run b
Mean 127.5 214.8 1168.2 127.0 180.3 105.2 178.2
SD 10.8 12.5 15.6 9.1 5.6 6.4 6.8
CV (%) 8.5 5.8 1.3 7.1 3.1 6.1 3.8
CV, coefficient of variation; SD, standard deviation. a Based on CLSI EP5-A2 tested using three controls, two runs
per day in duplicate for 20 days (total n = 80). b Based on one run of 20 tests.
A method comparison study was performed comparing quantification by NMR to platforms
commonly used for determining ketone body concentrations—LC/MS/MS for β-HB and AcAc and
GC/MS for acetone. A comparison of plasma concentrations using the comparator platforms correlated
well by Deming regression with R2 values of 0.996, 0.994 and 0.994 for β-HB, AcAc and acetone,
respectively (Figure 3A–C). The Bland–Altman plots revealed that the residuals, while randomly
dispersed, showed a slight bias toward higher results for β-HB and acetoacetate when quantified by
NMR compared to the LC/MS/MS assay (Figure 3D–E). For acetone, the residuals were not randomly
dispersed, and they trended downward at the higher concentrations. In addition, there was a bias
toward lower results when quantified by NMR compared to the GC/MS assay (Figure 3F). However,
when standard curves were used to evaluate the accuracy of the different methods, the NMR results
more closely reflected the known concentrations of the three ketone bodies (data not shown). For all
three analytes, only one specimen can be considered outside the limits of agreements (LOAs).
Four types of specimen collection tubes were evaluated for their suitability in the ketone body
assay. Results from specimens collected in plain red-top serum, EDTA plasma and heparin plasma tubes
were plotted against LipoTube results and linear regression analyses were performed. Supplementary
Table S1 summarizes the linear regression characteristics for the tube comparisons. Results indicate
that there was minimal (<2%) bias for β-HB and acetone in plain serum, EDTA plasma or heparin
plasma tubes versus serum collected in LipoTubes for β-HB and acetone. AcAc levels were somewhat
lower in all three tubes versus LipoTubes.
The stability of the three ketone bodies was evaluated in serum samples stored at room temperature,
refrigerated (2–8 ◦C), or frozen (<−70 ◦C). Results demonstrated that β-HB was stable up to 48 h at
room temperature and up to 72 h when refrigerated (2–8 ◦C) (Supplementary Table S2). AcAc and
acetone were stable up to 15 days when frozen <−70 ◦C. While acetone was stable when stored at room
temperature for 8 or 24 h, or when refrigerated for 24–48, AcAc was not. All three analytes were stable
for up to three freeze–thaw cycles. While AcAc and acetone were unstable (Bias = −28.2 and 22.5%,
respectively, after 3 years and −13.8 and 19.1%, respectively, after 6 years), β-HB was stable for 3 and 6
years when frozen at <−70 ◦C (Bias = 0.0% and −1.5%).
A population of generally healthy adult men and women (n = 552) was used to determine the
reference intervals for the analytes reported by the ketone body assay. Table 2 shows the distribution
of values for total ketone bodies, β-HB, AcAc and acetone in this population. For total ketone bodies,
β-HB, AcAc and acetone, the mean ± the standard deviation (SD) were 212.9 ± 133.8, 139.3 ± 91.5,
42.5 ± 28.8 and 31.2 ± 22.8 µM and the reference intervals were 88.8–623.2, 48.6–396.4, 26.3–120.0 and
19.7–78.6 µM, respectively (Table 2). There were no differences detected between the medians in the
women (n = 337) versus the men (n = 215) in this population (data not shown).
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Table 2. Distribution of the analytes reported by the ketone body assay in 552 generally healthy,
non-fasting adults.
Percentile Total KetoneBodies (µM)
β-hydroxybutyrate
(µM) Acetoacetate (µM) Acetone (µM)
0% <65.0 <45.0 <26.3 <19.7
2.5% 88.8 48.6 <26.3 <19.7
25.0% 136.9 88.8 <26.3 <19.7
50.0% 174.1 111.3 35.7 26.8
75.0% 235.8 154.1 49.7 37.8
97.5% 623.2 396.4 120.0 78.6
100% 1130 714.7 279.8 271.8
To confirm the reference intervals, we reanalyzed NMR spectra (n = 177,000) collected over several
months in the clinical NMR laboratory from fasting and non-fasting individuals whose serum samples
were sent for the NMR LipoProfile test. The distributions of the concentrations for total ketone bodies,
β-HB, AcAc and acetone in these subjects can be found in Supplementary Table S2. The means ±
the SD in this population were 287.0 ± 365.7, 193.6 ± 252.4, 48.9 ± 46.5 and 44.5 ± 84.7 µM and the
reference intervals were 7.5–987.1, 49.5–693.9, 26.3–143.4 and 19.7–179.5 µM for total ketone bodies,
β-HB, AcAc and acetone, respectively (Supplementary Table S3).
3.2. Cross-Sectional Analysis of Ketone Bodies in a Cohort of Subjects with Metabolic Disease
In the IRAS, T2DM subjects were older compared to non-diabetic subjects (Table 3). T2DM
subjects were also more likely to have higher systolic blood pre sure, BMI, waist circumference, fasting
glucose, 2 h glucose, free fatty acids (FFAs), triglycerides and GlycA, an NMR-based marker of systemic
inflammation that is associated with T2DM and cardiovascular disease [28,29]. They were also more
likely to have lower HDL-C and impaired insulin sensitivity, the latter exemplified by having higher
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mean LP-IR scores. In addition, total ketone bodies, β-HB, AcAc and acetone were significantly higher
in IRAS participants with T2DM compared to those who did not have T2DM at study start (Table 3).
Table 3. Baseline clinical and laboratory characteristics in the Insulin Resistance Atherosclerosis Study
(IRAS).
Characteristics Non-Diabetic Subjects(n = 825)
T2DM Subjects
(n = 373) p-Value
Age (years) 55 ± 8 57 ± 8 <0.0001
Sex, men (%) 467 (57) 194 (52) 0.14
Race
Non-Hispanic white (%) 334 (40) 128 (34) 0.04
Hispanic (%) 272 (33) 119 (32) 0.72
African American (%) 219 (27) 126 (34) 0.01
SBP (mmHg) 122 ± 17 129 ± 18 <0.0001
DBP (mmHg) 78 ± 9 78 ± 9.9 0.42
BMI (kg/m2) 28.4 ± 5.6 31.5 ± 5.6 <0.0001
Waist circumference (cm) 90 ± 13 99 ± 12 <0.0001
Fasting glucose (mmol/L) 5.5 ± 0.6 9.7 ± 3.2 <0.0001
2 Hour glucose (mmol/L) 6.9 ± 1.9 17.7 ± 4.8 <0.0001
Fasting FFAs (mmol/L) 0.47 ± 0.19 0.60 ± 0.23 <0.0001
Total cholesterol (mmol/L) 5.44 ± 1.11 5.51 ± 1.12 0.33
HDL-C (mmol/L) 1.21 ± 0.39 1.05 ± 0.30 <0.0001
Triglycerides (mmol/L) 1.24 (0.88–1.81) 1.77 (1.19–2.46) <0.0001
GlycA (µM) 346 ± 70 373 ± 71 <0.0001
LP-IR score (0–100) 50 ± 21 62 ± 18 <0.0001
Total ketone bodies (µM) 142 (98–208) 182 (116–269) <0.0001
β-hydroxybutyrate (µM) 100 (67–154) 131 (79–193) <0.0001
Acetoacetate (µM) 26 (13–44) 32 (15–52) 0.011
Acetone (µM) 15 (8–24) 18 (10–30) 0.0004
Data are the mean ± SD or the median (interquartile ranges). Abbreviations: BMI, body mass index; DBP, diastolic
blood pressure; FFAs, free fatty acids; HDL-C, high-density lipoprotein cholesterol; LP-IR, Lipoprotein Insulin
Resistance Index; SBP, systolic blood pressure; T2DM, type 2 diabetes mellitus. Triglycerides, insulin, total ketone
bodies, β-hydroxybutyrate, acetoacetate and acetone values were loge transformed.
Univariate analysis demonstrated that in the IRAS, total ketone bodies, β-HB, AcAc and acetone
were directly associated with FFAs, glucose and T2DM. Total ketone bodies and β-HB were inversely
associated with TG, and insulin resistance as measured by LP-IR (Table 4). This was true in both
non-diabetic and diabetic IRAS participants.
Table 4. Univariate analysis of plasma total ketone bodies, β-hydroxybutyrate, acetoacetate and acetone
in fasting 1198 subjects (373 subjects with and 825 subjects without type 2 diabetes mellitus) in the
Insulin Resistance Atherosclerosis Study (IRAS).
Total
KB β-HB AcAc Acetone
r p-Value r p-Value r p-Value r p-Value
Age 0.057 0.050 0.057 0.048 0.028 0.328 0.004 0.884
Sex (men/women) 0.161 <0.0001 0.210 <0.0001 0.014 0.624 −0.028 0.337
Glucose 0.162 <0.0001 0.137 <0.0001 0.139 <0.0001 0.137 <0.0001
FFAs 0.294 <0.0001 0.306 <0.0001 0.155 <0.0001 0.176 <0.0001
TG −0.078 0.007 −0.099 0.0007 −0.178 0.541 0.047 0.104
LP-IR score −0.134 <0.0001 −0.157 <0.0001 −0.063 0.028 −0.000 0.990
T2DM (yes/no) 0.152 <0.0001 0.145 <0.0001 0.087 0.003 0.115 <0.0001
Unadjusted Spearman correlation coefficients (r). Abbreviations: AcAc, acetoacetate; β-HB, β-hydroxybutyrate;
FFAs, free fatty acids; KB, ketone bodies; LP-IR, Lipoprotein Insulin Resistance Index; T2DM, type 2 diabetes
mellitus; TG, triglycerides.
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Age- and sex-adjusted multivariable linear regression analysis demonstrated that total ketone
bodies, β-HB, AcAc and acetone were independently associated with FFAs and T2DM. Total ketone
bodies and β-HB were inversely associated with TG and insulin resistance, as measured by LP-IR
(Table 4). AcAc was directly associated with FFAs and T2DM and inversely associated with insulin
resistance, but was not associated with TG. Acetone was directly associated with FFAs and T2DM and
inversely associated with age, sex and insulin resistance (Table 5).
Table 5. Multivariable linear regression analysis of plasma total ketone bodies, β-hydroxybutyrate,
acetoacetate and acetone in fasting 1198 subjects (373 subjects with and 825 subjects without type 2
diabetes mellitus) in the Insulin Resistance Atherosclerosis Study (IRAS).
Total
KB β-HB AcAc Acetone
β p-Value β p-Value β p-Value β p-Value
Age −0.036 0.188 −0.030 0.273 −0.020 0.494 −0.073 0.011
Sex (men/women) 0.013 0.820 0.064 0.265 −0.079 0.191 −0.136 0.026
FFAs 0.326 <0.0001 0.336 <0.0001 0.215 <0.0001 0.199 <0.0001
TG −0.132 <0.0001 −0.168 <0.0001 −0.035 0.301 0.019 0.581
LP-IR score −0.115 0.0005 −0.108 0.0009 −0.110 0.001 −0.072 0.037
T2DM (yes/no) 0.231 0.0003 0.240 0.0001 0.131 0.049 0.168 0.012
β: standardized regression coefficient. Abbreviations: AcAc, acetoacetate; β-HB, β-hydroxybutyrate; FFAs, free
fatty acids; KB, ketone bodies; LP-IR, Lipoprotein Insulin Resistance Index; T2DM, type 2 diabetes mellitus; TG,
triglycerides. Independent variables included are age, sex, FFAs, TG, LP-IR score and T2DM categorization.
4. Discussion
Here, we present an NMR-based method of measuring ketone bodies by deconvolution using
non-negative linear least squares algorithm. Another NMR-based method to quantify these analytes [35]
has been reported. However, it differs from the assay presented here in terms of the computational
method used to extract the analyte concentrations. While signal lineshape deconvolution was used for
the current assay, Wang and coworkers used Bayesian regression to develop their NMR-based method.
These approaches, irrespective of the computational method, can be used to measure ketone bodies by
NMR as an alternative to existing test strip and colorimetric-spectrophotometric assays.
This study is the first to evaluate a newly developed NMR-based test that quantifies ketone
bodies using a deconvolution assay on a clinical NMR analyzer. It is clear from this study that if one
wishes to quantify circulating AcAc and acetone, samples need to be frozen at <−70 ◦C immediately
after collection and processing of the specimen tubes and tested immediately after thawing due to
the instability of these two analytes. This is consistent with previous publications that evaluated the
stability of AcAc which tends to become rapidly decarboxylated [36,37] when samples are not frozen at
<−70 ◦C. Many protocols call for the deproteinization of samples before analysis in order to preserve
AcAc. However, this is not practical for NMR analysis under clinical laboratory conditions. β-HB,
on the other hand, is very stable under all conditions tested and the β-HB assay exhibited very good
analytical performance characteristics. Therefore, while we are able to quantify levels of total ketone
bodies, β-HB, AcAc and acetone in carefully collected and stored samples, β-HB is the preferred ketone
body for clinical evaluation. One of the strengths of NMR-based tests is that after the NMR spectrum
is collected, it is quick and easy to quantify multiple analytes simultaneously from the same spectrum.
Therefore, while an NMR-based assay for β-HB may not be useful for point-of-care testing, it may
be useful for measuring β-HB along with glucose, branched chain amino acids [16] and other diet
related metabolites and nutrients [38] and presenting the results in a panel that may inform a patient
or physician about the potential effects of their diet or drug treatment.
While there are guidelines for concentrations of ketone bodies and β-HB that can be used to
identify individuals with diabetic or alcoholic ketoacidosis (>1.0–1.5 mM), normal reference intervals
have not been well established in the literature. We sought to determine the reference intervals for total
ketone bodies, β-HB, AcAc and acetone in two different populations, a generally healthy population
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of men and women as well as a large population of subjects whose serum samples had been sent to
LabCorp’s NMR laboratory. The reference intervals in the cohort of generally healthy subjects were
somewhat lower than those previously reported in 100 subjects after an overnight fast [39]. However,
similar to the findings of Foster, et al., there were no significant differences between genders in the
reference intervals for total ketone bodies, β-HB, AcAc or acetone [39]. While the median values for
the ketones in the small and large cohorts in our study were similar, the large cohort contained a few
individuals who had very high ketone levels. Notably, for uncertain reasons, 0.5%–1.0% had greater
than the recommended cutoff for elevated ketone levels (>1.5 mM) with a number of patients with
severe ketosis (146 subjects with total ketones >5.0 mM and 19 subjects >10.0 mM).
To confirm that the newly developed NMR-based ketone body assay measures clinically relevant
levels of ketone bodies, β-HB, AcAc and acetone were measured in the IRAS. Total ketone bodies,
β-HB, AcAc and acetone were significantly higher in IRAS participants with T2DM compared to
non-diabetic subjects. Additionally, total ketone bodies and β-HB were independently associated
with FFAs and T2DM and inversely associated with insulin resistance. Ketone bodies are products
of fatty acid catabolism that are used as alternative sources of energy to glucose when carbohydrate
intake is low and there is a surplus of circulating FFAs [1]. FFAs are transported to the liver where
they are oxidized to form acetyl CoA which can in part be converted to ketone bodies. Therefore,
it was not surprising that total as well as the individual ketone bodies were correlated with fasting
FFA levels in the IRAS. It is interesting, and possibly relevant, that higher total ketone bodies and
β-HB were associated with lower insulin resistance in the IRAS cohort. The LP-IR Index was used as a
measure of insulin resistance in this study. As opposed to HOMA-IR, which is dependent on glucose
and insulin, LP-IR relies on NMR-measured lipoprotein parameters and is heavily weighted by large
very-low-density lipoprotein (VLDL) particles [22]. The direct relationship with FFAs and the inverse
relationship between total ketone bodies and TG and the LP-IR scores is not surprising in this context.
In other words, as TG are catabolized as the preferred energy substrate over glucose, large VLDL will
decrease as will LP-IR levels. Moreover, while the inverse relationship between ketone bodies and
LP-IR was significant, the correlation was not very strong (r = −0.134, p < 0.0001) suggesting that there
is not as close a relationship between them as there is between LP-IR and TG (r = 0.694, p < 0.0001).
With that said, it is interesting that subjects on a ketogenic diet experience a reduction in insulin
resistance and a concomitant mild increase in circulating ketone bodies [6,7]. In addition, patients
on SGLT2 inhibitors to control their T2DM experience a reduction in insulin resistance, as measured
by HOMA-IR, as well as a mild increase in circulating ketone bodies [8–10]. Taken together, these
observations suggest that the mildly elevated ketone body concentrations that have been observed
with consumption of a ketogenic diet or with SGLT2 treatment may reflect metabolic improvement
with respect to insulin sensitivity. Furthermore, these observations may be more related to fatty acid
and TG metabolism than to glucose metabolism under certain metabolic conditions.
Several strengths and limitations of the present study should be acknowledged. We consider it a
strength that the assay is reliable at a low to intermediate range of ketone body values. In addition, the
direct association of total ketone bodies with FFAs, and its inverse association with TG and insulin
resistance was observed in a large, multi-ethnic cohort of subjects with varying degree of metabolic
impairment. However, the cross-sectional design of this study does not allow one to address the nature
of the observed relationships, nor to exclude the possibility of reverse causation.
5. Conclusions
In conclusion, ketone body levels can be obtained by NMR with sufficient precision and accuracy
for clinical use. Further, total ketone bodies were mildly elevated in patients with T2DM and were
associated with fasting FFAs and inversely associated with TG and insulin resistance.
Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/2/321/s1,
Supplementary Figure S1. Linearity of expected versus NMR-measured (A) β-hydroxybutyrate, (B) acetoacetate,
and (C) acetone in serum. Supplementary Table S1. Linear regression results for tube comparison study; plain
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red-top serum, EDTA plasma tubes and sodium heparin plasma tubes compared to the Greiner LipoTube.
Supplementary Table S2. Stability of ketone bodies at different storage conditions and multiple freeze–thaw cycles
Supplementary Table S3. Distribution of the analytes reported by the ketone body assay in 177,000 fasting and
non-fasting subjects whose serum samples were tested in the clinical NMR laboratory.
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CV% coefficient of variation
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